 |
|
|
| |
Response to DAA-based regimens in HIV-HCV co-infected patients in real-life, France
....patients with avg Fibroscan of 14.2 kPa / 67% of patients cirrhotic
|
| |
| |
Reported by Jules Levin
CROI 2016 Feb 22-24 Boston
L. Piroth1, L. Wittkop2,3,4, K. Lacombe5, E. Rosenthal6, C. Gilbert2, P. Carrieri7,8, F. Dabis2,3,4, P. Sogni9,10, D. Salmon11,12 for the ANRS CO13 HEPAVIH
1Department of Infectiology, CHU Dijon, Dijon, France. 2INSERM, ISPED, Centre INSERM U1219- Epidemiologie-Biostatistique, Bordeaux, France. 3CHU de Bordeaux, Pôle de Sante Publique, Service d’Information Medicale, Bordeaux, France. 4Universite de Bordeaux, ISPED, Centre INSERM U1219-Epidemiologie-Biostatistique, Bordeaux, France. 5Department of Infectious Diseases, Saint-Antoine Hospital, AP-HP, Paris, France. 6Department of Internal Medicine, CHU de Nice, Archet Hospital, University of Nice Sophia Antipolis,Nice, France. 7INSERM, U912 (SE4S)-University of Aix Marseille, IRD, France. 8UMR-S912-ORS PACA, Marseille, France. 9Hepatology Unit, Cochin Hospital, AP-HP, Paris, France. 10Cochin Institute, INSERMU1016, Paris, France. 11Department of Internal Medicine and Infectious Diseases, Cochin Hospital, AP-HP, Paris, France. 12Paris Descartes University, Sorbonne Paris Cite, Paris, France.
|
| |
|
|
|
|
|
